Emergence of Fosfomycin Resistance by Plasmid-Mediated <i>fos</i> Genes in Uropathogenic ESBL-Producing <i>E. coli</i> Isolates in Mexico
Mario Galindo-Méndez,
Humberto Navarrete-Salazar,
Francisco Baltazar-Jiménez,
Eduardo Muñoz-de la Paz,
María Fernanda Sánchez-Mawcinitt,
Alexis Gómez-Pardo,
Elvira Garza-González,
Luis Alfredo Ponce-de-León-Garduño,
Rafael Franco-Cendejas,
Rayo Morfín-Otero,
Fabián Rojas-Larios,
Juan Pablo Mena-Ramírez,
Cecilia Teresita Morales-de-la-Peña,
Lourdes García-Mendoza,
Elena Victoria Choy-Chang,
Laura Karina Avilés-Benítez,
Eduardo López-Gutiérrez,
Jorge Luis Canizales-Oviedo,
Nicolás Eric Barlandas-Rendón,
Joyarib Yanelli Maldonado-Anicacio,
Alina Aracely Rosales-García,
Heidy Leticia Ostos-Cantú
Affiliations
Mario Galindo-Méndez
Laboratorios Galindo SC, Department of Microbiology, Oaxaca 68000, Mexico
Humberto Navarrete-Salazar
School of Medicine, Universidad Anáhuac Oaxaca, San Raymundo Jalpan 71248, Mexico
Francisco Baltazar-Jiménez
School of Medicine, Universidad Anáhuac Oaxaca, San Raymundo Jalpan 71248, Mexico
Eduardo Muñoz-de la Paz
School of Medicine, Universidad Anáhuac Oaxaca, San Raymundo Jalpan 71248, Mexico
María Fernanda Sánchez-Mawcinitt
School of Medicine, Universidad Anáhuac Oaxaca, San Raymundo Jalpan 71248, Mexico
Alexis Gómez-Pardo
Hospital General Balbuena, Ciudad de México 15970, Mexico
Elvira Garza-González
Hospital Universitario Dr. José E. González, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
Luis Alfredo Ponce-de-León-Garduño
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México 14080, Mexico
Rafael Franco-Cendejas
Instituto Nacional de Rehabilitación Luis Guillermo Ibarra, Ciudad de México 14389, Mexico
Rayo Morfín-Otero
Hospital Civil de Guadalajara e Instituto de Patología Infecciosa, Guadalajara 44280, Mexico
Fabián Rojas-Larios
Hospital Regional Universitario de Colima, Colima 28085, Mexico
Juan Pablo Mena-Ramírez
Hospital General de Zona 21 Tepatitlán De Morelos, Centro Universitario de los Altos (CUALTOS), Universidad de Guadalajara, Tepatitlán de Morelos 47620, Mexico
Cecilia Teresita Morales-de-la-Peña
Hospital General con Especialidades Juan María de Salvatierra, La Paz 23085, Mexico
Lourdes García-Mendoza
Hospital Angeles Valle Oriente, San Pedro Garza García 66260, Mexico
Elena Victoria Choy-Chang
Hospital General de Zona No. 1, Tapachula 30700, Mexico
Laura Karina Avilés-Benítez
Hospital Infantil de Morelia, Morelia 58000, Mexico
Eduardo López-Gutiérrez
Hospital Regional de Alta Especialidad de Oaxaca, San Bartolo Coyotepec 71256, Mexico
Jorge Luis Canizales-Oviedo
Laboratorio Pueblo Nuevo, Centro Universitario de Salud, Universidad Autónoma de Nuevo León, Monterrey 66455, Mexico
Nicolás Eric Barlandas-Rendón
Laboratorio Bioclin, Chilpancingo 39000, Mexico
Joyarib Yanelli Maldonado-Anicacio
Hospital general de Chilpancingo, Chilpancingo 39019, Mexico
Alina Aracely Rosales-García
Hospital de Especialidades pediátrico de León, León 39900, Mexico
Fosfomycin is currently a viable option against urinary tract infections, particularly against extended-spectrum β-lactamases (ESBL)-producing E. coli, due to its unique mechanism of action and its low resistance among bacteria. The objective of this study was to investigate two of the three most common mechanisms of resistance against this antibiotic among 350 ESBL-producing E. coli strains isolated from the urine of Mexican patients. The prevalence of fosfomycin resistance in our study was 10.9% (38/350). Of all resistant isolates analyzed, 23 (60.5%) were identified as fos-producing organisms, with 14 strains carrying fosA3 and 9, fosA1. Additionally, 11 (28.9%) fosfomycin-resistant isolates presented resistance due to impaired antibiotic transport and 8 (21.0%) both mechanisms. No resistance mechanism investigated in the study was found on 12 strains. All 38 confirmed ESBL-producing isolates carried a blaCTX-M subtype, 36 (94.5%) belonged to the O25b-ST131 clone, and all of them were able to transfer the fosfomycin resistance trait to recipient strains horizontally. This is the first study in Mexico demonstrating a plasmid-mediated fosfomycin resistance mechanism among clinical E. coli strains. Since our results suggest a strong association among fos and blaCTX-M genes and ST131 clones in uropathogenic E. coli, plasmid-mediated fosfomycin resistance should be closely monitored.